ERBB2 and breast cancer: Histopathologically, there were 8 (44%) luminal B-like BC cases, 7 (39%) HER2-positive cases, 1 (5.5%) TNBC case, and 2 (11%) unidentifiable molecular subtype cases in the LTS group.